Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093223 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of ABI-007 for In-Stent Restenosis
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00093223 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 76 participants.
The verdict
NCT00093223, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse events.
Interventions
- DRUG Paclitaxel Nanoparticle Albumin Bound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2001-09-01 |
| Est. Completion | 2007-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093223
The ClinicalTrials.gov registry entry for NCT00093223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel Nanoparticle Albumin Bound is the first listed.
NCT00093223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093223 about?
NCT00093223 is a clinical study titled "A Safety Study of ABI-007 for In-Stent Restenosis". This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the...
What is the current status of trial NCT00093223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2001-09-01. Estimated completion is 2007-12-01.
What interventions are being tested in trial NCT00093223?
The interventions under investigation include: Paclitaxel Nanoparticle Albumin Bound (DRUG).
Who is sponsoring clinical trial NCT00093223?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.